Blueprint Medicines (Italy) S.r.l.

EFPIA Disclosure

Methodology Note

JUNE 30, 2026

Introduction

The European Federation of Pharmaceutical Industries and Associations (EFPIA) introduced disclosure requirements in 2014 to promote transparency in the pharmaceutical industry. Blueprint Medicines fully supports this initiative and values its collaboration with healthcare professionals (HCPs) and healthcare organizations (HCOs).

This methodological note explains how Blueprint Medicines interprets and implements the requirements of the EFPIA Disclosure Code, providing context for the disclosed data and outlining its relationships with HCPs and HCOs.

Blueprint Medicines complies with all applicable laws and aligns its reporting with the most rigorous standards where local requirements differ from those of EFPIA.

Contents

1. Definitions

1.1 Data Subjects

Healthcare Professional (HCP): any natural person who is a member of the medical, dental, pharmaceutical, or nursing professions, or any other person who, in the course of their professional practice, may prescribe, purchase, supply, recommend, or administer a Medicinal Product, and whose principal place of business, principal professional address, or place of incorporation is located in Europe.

Healthcare Organization (HCO): any legal entity or organization (i) that is a healthcare, medical, or scientific association or organization (regardless of its legal or organizational form), such as a hospital, clinic, foundation, university, or other educational institution or scientific society (with the exception of Patient Associations as defined in Article 21) whose registered office, place of incorporation, or principal place of business is located in Europe; or (ii) through which one or more HCPs provide services.

Treatment of Retired and Deceased HCPs: Transfers of Value (ToVs) are disclosed for all healthcare professionals who received a ToV during the reporting period, including those who have since retired or passed away. The disclosure reflects the status at the time of the interaction.

If Blueprint Medicines is contacted by family members or an employer regarding a deceased healthcare professional, we will handle the situation on a case-by-case basis.
Where possible and appropriate, data will be disclosed in aggregate form

1.2 Expenditure Categories Donations and Grants

Financial contributions to support:

- Medical or scientific research
- Medical or scientific education
- Health programs aimed at improving health outcomes (e.g., disease screening)

- Scholarships and Fellowships

Sponsorship Agreements

For events organized by third parties (e.g., Professional Conference Organizers, Medical and Scientific Societies), Blueprint Medicines may enter into sponsorship agreements covering:

- Company-sponsored satellite symposia featuring scientific presentations
- Rental of booths to provide scientific information at the request of HCPs
- Sponsorship of speakers or instructors (selected by the event organizer, without influence from Sanofi)
- Sponsorship of educational/training courses (participant selection independent of Sanofi)

Contributions toward event costs

Events include any scientific or educational gathering (e.g., congresses, conferences, symposia, advisory boards, training sessions) organized by or on behalf of Blueprint Medicines, sometimes including hospitality where permitted.
Most events are managed by third parties (e.g., conference agencies, travel agencies) through service agreements that include lists of participants and their terms of value (ToV).

Compensation for services and consulting

Blueprint Medicines regularly engages external experts to provide services in medical or scientific fields where Sanofi has legitimate needs and lacks in-house expertise.

These services include:

- Presenting at or chairing scientific meetings
- Participation on boards and committees
- Medical training and education
- Consulting

All agreements are documented in written contracts that specify the purpose, rationale, and deliverables prior to the provision of the service.

Related expenses agreed upon in the service or consulting contract

Related expenses agreed upon in the service or consulting contracts cover reasonable expenses related to lodging, airfare, and ground transportation incurred by the Expert in the performance of the service.

2. Scope of Disclosure

2.1 Products involved

Prescription-only medicines (POM)

2.2 Company involved

Blueprint Medicines (Italy) S.r.l.

2.3 Excluded Transactions

The following are excluded from disclosure:

- Gifts of negligible value related to the practice of the profession (already governed by strict legal and/or ethical provisions)
- Meals and beverages provided at scientific events
- Medical devices
- Drug samples

2.4 Transaction payment date

Depending on the type (direct or indirect) and nature (cash or in-kind) of the transfers of value, two conventions apply:

- **Direct ToVs**: The date used is the "clearing date" from our financial system, corresponding to the date the bank transfer is credited to the recipient's account;
- **Event-related ToVs**: For ToVs linked to an event (e.g., conference registration, travel, hotel), all transfers of value are reported using the date corresponding to the first day of the event.

2.5 Direct Transactions

Transfers of value made directly by Blueprint Medicines for the benefit of a recipient.

2.6 Indirect Transactions

Transfers of value made on behalf of Blueprint Medicines for the benefit of a recipient, or transfers of value made through an intermediary (i.e., a third party) where Blueprint Medicines knows or can identify the recipient who will benefit from the transfer of value.

2.7 Non-monetary Transactions

A non-monetary transfer of value refers to any benefit provided to a relevant recipient without a direct monetary payment.
Examples include travel and lodging for attending conferences, registration fees for educational events, and other benefits in kind.

If the benefit is provided through a third party (e.g., the event organizer), the value is attributed to the recipient and disclosed under the recipient's name.

2.8 Transactions in the Case of Partial Attendance, Cancellation, or Refunds

No-shows and last-minute cancellations are not reported if no benefit was provided to the HCP. However, if the benefit was paid for by the company but not used by the HCP, the amount will be disclosed in the aggregated section of the report.

2.9 Cross-Border Activities

Cross-border transfers of value to the relevant recipients are disclosed in accordance with applicable transparency regulations, with reporting responsibilities assigned to the affiliate in the recipient's country of operation.

2.10 R&D

Blueprint Medicines discloses all transfers of value related to R&D activities in the aggregated R&D section when they are linked to the planning or conduct of:

- Nonclinical studies (*OECD Principles of Good Laboratory Practice*)
- Clinical studies (*EU Directive 2001/20/EC*)
- Prospective non-interventional studies involving the collection of patient data.

Retrospective non-interventional studies are also included in the aggregate R&D category, as they follow the same processes and ethical standards as prospective studies.

Externally Sponsored Research (ESR) studies are included in the aggregate R&D disclosure because these studies fall under the classification outlined above.

2.11 Voluntary Disclosure

Not applicable

3. Specific considerations

3.1 National Unique Identifier

Blueprint Medicines uses internal and external identifiers to ensure that each transfer of value is accurately matched to the correct recipient.

3.2 Self-incorporated HCP

When payments are made to a self-incorporated HCP through which an individual healthcare professional provides services, the disclosure must be made in the name of the individual HCP who performed the services.

3.3 Multi-Year Agreements

Multi-year agreements cover a series of services or sponsored activities/events that span multiple years. Transfers of value associated with these agreements are disclosed based on the relevant reporting period.

3.4 Country-specific requirements

Cross-Border Value Transfers

The cross-border transfer of value is reported in the country where the recipient's primary address is located.

Sponsorship Disclosure

In Italy, in the case of sponsorships, if the actual beneficiary cannot be clearly identified, the transfer of value will be disclosed under the name of the organization or agency managing the event.

Consent to Disclosure

In Italy, all Healthcare Organizations (HCOs) provide consent by default in accordance with regulatory requirements.

3.5 Quality Checks

Blueprint Medicines applies rigorous quality checks to ensure accuracy and compliance, to the best of its knowledge, prior to disclosure. These include validating the details of the relevant recipients, verifying financial data, reviewing reporting categories, removing duplicates and ToVs outside the scope, adding consent, and completing the internal review and certification prior to publication.

4. Legal Basis for Data Protection

4.1 Obtaining Consent for Transparency

Consent to transparency applies exclusively to EFPIA disclosure requirements. It determines whether transfers of value are disclosed individually, with the recipient's name, or in aggregate form.

Obtaining Informed Consent

Blueprint Medicines does not obtain informed consent from the relevant recipients when required by the Farmindustria Code. Consent is not obtained via a Data Collection Form, therefore, related transfers of value for that fiscal year are reported in aggregate form.

5. Disclosure Template

5.1 Publication Date

Transfers of value are published annually on June 30.

5.2 Disclosure platform

Platform: **www.blueprintmedicines.com**

5.3 Language of disclosure

The disclosure data is available in Italian on the platform.

6. Financial Data Disclosure

6.1 Currency

Local transfers of value are always made and recorded in the currency of the relevant recipient.

6.2 Inclusion or Exclusion of VAT

Whether VAT is included, if applicable, in the disclosed transfers of value depends on the data source: transfers recorded in the corporate financial system (SAP SHIFT) include VAT, while indirect payments and data from the local E&C 1CRM are reported net of VAT.

6.3 VAT Application Parameters

Blueprint Medicines applies the following calculation principles for transfers of value:

- **Indirect payments**: For payments made through third parties or Blueprint Medicines affiliates outside of Italy, it is not always possible to determine whether the payments include or exclude VAT, and the payment date is known
- **Currency conversion**: When payments are made in different currencies, the conversion is based on the exchange rate at the time of payment or on a standard monthly corporate rate provided directly by the transparency tool
- **Event-related costs**: For multi-component events (e.g., travel, lodging, registration), all costs are reported in aggregate, are dated as the first day of the event (as per the EFPIA convention), and are exclusive of VAT.

7. Additional Information

Personal Data Protection

Blueprint Medicines is committed to protecting HCPs' personal data and complying with applicable data protection laws and regulations.

HCPs are informed of their right to request, at any time, access to their personal data held by Blueprint Medicines and to request the correction or deletion of inaccurate data.

Contact Information
GlobalTransparency *GlobalTransparency@sanofi.com*